

James Signorovitch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4343439/publications.pdf>

Version: 2024-02-01

102
papers

2,804
citations

257450

24
h-index

189892

50
g-index

102
all docs

102
docs citations

102
times ranked

4938
citing authors

#	ARTICLE	IF	CITATIONS
1	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2018, 138, 1387-1398.	1.6	468
2	Intrinsic Circadian Clock of the Mammalian Retina: Importance for Retinal Processing of Visual Information. <i>Cell</i> , 2007, 130, 730-741.	28.9	389
3	Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis. <i>Chest</i> , 2014, 146, 142-151.	0.8	191
4	Correcting for ascertainment biases when analyzing SNP data: applications to the estimation of linkage disequilibrium. <i>Theoretical Population Biology</i> , 2003, 63, 245-255.	1.1	134
5	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. <i>Circulation</i> , 2017, 136, 1772-1780.	1.6	134
6	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021, 9, 65-73.	4.1	93
7	Linkage Disequilibrium and Inference of Ancestral Recombination in 538 Single-Nucleotide Polymorphism Clusters across the Human Genome. <i>American Journal of Human Genetics</i> , 2003, 73, 285-300.	6.2	76
8	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. <i>Hypertension</i> , 2008, 51, 48-54.	2.7	69
9	The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2015, 357, 8-18.	0.6	61
10	Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. <i>Neurological Sciences</i> , 2016, 37, 165-179.	1.9	57
11	Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2019, 14, e0221097.	2.5	57
12	Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. <i>PLoS ONE</i> , 2016, 11, e0164684.	2.5	51
13	Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. <i>Quality of Life Research</i> , 2011, 20, 1737-1744.	3.1	42
14	Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 130-137.	1.9	41
15	Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. <i>Muscle and Nerve</i> , 2020, 61, 26-35.	2.2	40
16	Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1550-1557.	1.1	39
17	Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 119-128.	2.6	38
18	Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. <i>PLoS ONE</i> , 2014, 9, e114264.	2.5	35

#	ARTICLE	IF	CITATIONS
19	Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI. <i>American Heart Journal</i> , 2020, 221, 165-176.	2.7	35
20	A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?. <i>Advances in Therapy</i> , 2020, 37, 3040-3058.	2.9	34
21	Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. <i>Experimental Hematology and Oncology</i> , 2013, 2, 32.	5.0	32
22	Effect of Adherence and Insulin Delivery System on Clinical and Economic Outcomes among Patients with Type 2 Diabetes Initiating Insulin Treatment. <i>Value in Health</i> , 2015, 18, 198-205.	0.3	32
23	Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 275-285.	1.4	30
24	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. <i>JACC: Heart Failure</i> , 2019, 7, 717-724.	4.1	29
25	Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 177-189.	1.4	28
26	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. <i>Neurology</i> , 2020, 95, e1381-e1391.	1.1	27
27	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 39-52.	2.6	24
28	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. <i>PLoS ONE</i> , 2020, 15, e0232870.	2.5	23
29	Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1065-1072.	3.0	20
30	Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. <i>Journal of Medical Economics</i> , 2019, 22, 981-993.	2.1	20
31	Epilepsy treatment patterns among patients with tuberous sclerosis complex. <i>Journal of the Neurological Sciences</i> , 2018, 391, 104-108.	0.6	19
32	Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007022.	4.8	19
33	Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1946-1957.	2.9	19
34	Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018. <i>BMC Infectious Diseases</i> , 2022, 22, 294.	2.9	19
35	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	17
36	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2019, 22, 140-150.	2.1	17

#	ARTICLE	IF	CITATIONS
37	Real-world medication persistence with single versus multiple tablet regimens for HIV treatment. <i>Journal of the International AIDS Society</i> , 2014, 17, 19537.	3.0	16
38	Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 285-292.	7.7	16
39	Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 491-497.	1.4	16
40	Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective. <i>Current Medical Research and Opinion</i> , 2016, 32, 405-416.	1.9	14
41	Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. <i>Current Medical Research and Opinion</i> , 2019, 35, 105-111.	1.9	14
42	Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. <i>Clinical Therapeutics</i> , 2016, 38, 404-412.	2.5	13
43	An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. <i>Clinical Drug Investigation</i> , 2020, 40, 629-643.	2.2	13
44	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. <i>Neuromuscular Disorders</i> , 2022, 32, 271-283.	0.6	13
45	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	1.9	11
46	Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2018, 388, 168-174.	0.6	10
47	Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. <i>Journal of Medical Economics</i> , 2018, 21, 543-552.	2.1	10
48	Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Therapeutics</i> , 2019, 41, 2357-2379.e1.	2.5	10
49	Carbon footprint and associated costs of asthma exacerbation care among UK adults. <i>Journal of Medical Economics</i> , 2022, 25, 524-531.	2.1	10
50	Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. <i>Current Medical Research and Opinion</i> , 2011, 27, 1089-1096.	1.9	9
51	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 268.	2.7	9
52	Letter to the Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e333-e334.	2.0	9
53	The statistical performance of matching-adjusted indirect comparisons: Estimating treatment effects with aggregate external control data. <i>Annals of Applied Statistics</i> , 2020, 14, .	1.1	8
54	Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. <i>Value in Health</i> , 2015, 18, 824-831.	0.3	7

#	ARTICLE	IF	CITATIONS
55	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. <i>Journal of Medical Economics</i> , 2016, 19, 1187-1199.	2.1	7
56	Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study. <i>Blood</i> , 2018, 132, 4190-4190.	1.4	7
57	Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 129-139.	1.4	6
58	Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy. <i>Journal of Clinical Oncology</i> , 2021, 39, 4581-4581.	1.6	6
59	Increased Olanzapine Discontinuation and Health Care Resource Utilization Following a Medicaid Policy Change. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 787-794.	2.2	6
60	Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-376.	1.6	6
61	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
62	Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?. <i>CNS Drugs</i> , 2017, 31, 899-910.	5.9	5
63	Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2018, 35, 1035-1048.	2.9	5
64	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. <i>Pharmacoeconomics</i> , 2020, 38, 1201-1218.	3.3	5
65	Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study. <i>Journal of Clinical Oncology</i> , 2017, 35, 6605-6605.	1.6	5
66	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021. <i>PLoS ONE</i> , 2021, 16, e0261707.	2.5	5
67	Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. <i>American Journal of Therapeutics</i> , 2011, 18, 436-448.	0.9	4
68	Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. <i>Rheumatology and Therapy</i> , 2016, 3, 305-322.	2.3	4
69	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data. <i>BMJ Open</i> , 2018, 8, e021642.	1.9	4
70	Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis. <i>Journal of the Neurological Sciences</i> , 2019, 398, 163-170.	0.6	4
71	Real-World Clinical Burden of Sickle Cell Disease in the US Community-Practice Setting: A Single-Center Experience from the Foundation for Sickle Cell Disease Research. <i>Blood</i> , 2019, 134, 5856-5856.	1.4	4
72	The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States. <i>Advances in Therapy</i> , 2022, 39, 943-958.	2.9	4

#	ARTICLE	IF	CITATIONS
73	Association between time to progression and subsequent survival in ceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2016, 32, 1911-1918.	1.9	3
74	Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 273-279.	1.4	3
75	Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 737-750.	1.4	3
76	Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1065-1078.	1.4	3
77	Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r) Tj ETQq1 1 0.784314 rgBT /Over	1.4	3
78	PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/human endocrine receptor negative (HER2 ⁺) metastatic breast cancer (mBC): A meta-analysis of published clinical trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 1069-1069.	1.6	3
79	1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018. <i>Open Forum Infectious Diseases</i> , 2020, 7, S741-S742.	0.9	3
80	1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018. <i>Open Forum Infectious Diseases</i> , 2020, 7, S740-S741.	0.9	3
81	<sc>Long-term</sc> treatment effects of inotersen on <sc>health-related</sc> quality of life in patients with <sc>ATTR</sc> amyloidosis with polyneuropathy: Analysis of the <sc>open-label</sc> extension of the <sc>NEUROATR</sc> trial. <i>Muscle and Nerve</i> , 2022, 66, 438-446.	2.2	3
82	Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. <i>Journal of Medical Economics</i> , 2015, 18, 919-929.	2.1	2
83	Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 237-237.	1.6	2
84	Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 716-716.	1.6	2
85	Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma. <i>Future Oncology</i> , 2022, 18, 1321-1331.	2.4	2
86	Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. <i>Journal of Medical Economics</i> , 2022, 25, 817-825.	2.1	2
87	Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation. <i>Journal of Medical Economics</i> , 2022, 25, 940-953.	2.1	2
88	Validation of an ambient measurement system (AMS) for physical activities in a paediatric population. <i>Journal of Medical Engineering and Technology</i> , 2019, 43, 182-189.	1.4	1
89	Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. <i>Advances in Therapy</i> , 2019, 36, 3446-3457.	2.9	1
90	Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use. <i>Journal of Clinical Oncology</i> , 2021, 39, e18834-e18834.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. health plan population.. Journal of Clinical Oncology, 2017, 35, 6599-6599.	1.6	1
92	Variation in recurrence rate and overall survival (OS) outcomes by disease stage and incremental impact of time to recurrence on OS in localized renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, 4543-4543.	1.6	1
93	Response to The J-Point Revisited. Hypertension, 2008, 51, .	2.7	0
94	Incomparable Effectivenessâ€”Apples to Apples?â€”Replyâ€”I. Mayo Clinic Proceedings, 2010, 85, 764-767.	3.0	0
95	Response by Elming et al to Letter Regarding Article, â€œAge and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failureâ€• Circulation, 2018, 137, 2190-2190.	1.6	0
96	Abstract P90: Cardiovascular and Economic Outcomes Following Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	2.2	0
97	Indirect Comparisons: A Brief History and a Practical Look Forward. , 2017, , 265-276.		0
98	MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT). Journal of the Endocrine Society, 2019, 3, .	0.2	0
99	Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care. Neuropediatrics, 2019, 50, .	0.6	0
100	863. Pre-Exposure Prophylaxis (PrEP) Prescriptions among Individuals at High Risk for HIV in the United States, 2012-2018. Open Forum Infectious Diseases, 2021, 8, S523-S523.	0.9	0
101	Real-world treatment patterns in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC): Costs of tumor reduction procedures and their complications.. Journal of Clinical Oncology, 2022, 40, 4539-4539.	1.6	0
102	Factors associated with increased <sc>healthâ€related</sc> qualityâ€ofâ€life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen. Muscle and Nerve, 2022, 66, 319-328.	2.2	0